Truist Financial Corp Sells 4,780 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Truist Financial Corp lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 29.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,570 shares of the medical equipment provider’s stock after selling 4,780 shares during the period. Truist Financial Corp’s holdings in Lantheus were worth $929,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in LNTH. GAMMA Investing LLC lifted its holdings in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares in the last quarter. Fidelis Capital Partners LLC acquired a new stake in Lantheus in the 1st quarter worth about $34,000. FinTrust Capital Advisors LLC boosted its holdings in Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 232 shares during the period. Nkcfo LLC bought a new stake in Lantheus in the 2nd quarter valued at about $47,000. Finally, NBC Securities Inc. grew its position in shares of Lantheus by 28.4% during the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 191 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LNTH. JMP Securities cut their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. Truist Financial cut their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Leerink Partners increased their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Finally, B. Riley upped their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $126.00.

Lantheus Stock Performance

NASDAQ LNTH opened at $112.19 on Monday. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The stock has a market cap of $7.78 billion, a PE ratio of 17.13 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The firm’s fifty day moving average price is $104.20 and its two-hundred day moving average price is $89.50.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. During the same period in the previous year, the company earned $1.40 EPS. Lantheus’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, equities analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the completion of the sale, the director now owns 454,923 shares of the company’s stock, valued at approximately $43,445,146.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,981 shares of company stock worth $2,689,156 in the last ninety days. Company insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.